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Abstract
Background: Methadone maintenance therapy (MMT) is a proven treatment strategy for opioid dependent patients.
Although studies have demonstrated that MMT increases contact with the medical system and improves adherence to
antiretroviral therapy (ART) in HIV-positive people who inject drugs (PWID), the effect of MMT discontinuation on ART
discontinuation has not been well described.
Methods: We examined the impact of continuous MMT use, MMT non-use and MMT discontinuation on the time to
ART discontinuation (defined as 90 days of continuous non-use following previous enrolment) in a community-recruited
prospective cohort of HIV-positive PWID followed between May 1996 and May 2013 in Vancouver, Canada. Multivariate
Cox proportional hazards regression was used to examine the association between MMT use patterns and time to ART
discontinuation while adjusting for socio-demographic confounders.
Results: A total of 794 HIV-positive PWID were included during the study period. In an adjusted analysis, in comparison
to those who were continuously on MMT, MMT non-use (Adjusted Hazard Ratio [AHR] = 1.44, 95 % Confidence Interval
[CI]: 1.19–1.73) as well as discontinuing MMT (AHR = 1.82, 95 % CI: 1.27–2.60) were both found to be independently
associated with time to ART discontinuation.
Conclusions: This study reinforces the known benefits of MMT use on ART adherence and demonstrates how
discontinuation of MMT is independently associated with an increased risk of ART cessation. These data highlight
the importance of retaining PWID on MMT.
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Background
People who inject drugs (PWID) constitute a population
at exceptionally high-risk for HIV infection, representing
approximately 10 % of all new HIV infections in North
America annually [1, 2]. In addition to an increased risk
of HIV infection, PWID exhibit higher rates of disease
progression and higher HIV/AIDS mortality rates as a
result of increased co-morbidities and suboptimal access
to antiretroviral therapy (ART) [3–6]. There is also a
well-documented association between ongoing drug use
and decreased ART adherence [7, 8], which can lead to
the development of drug resistance [9, 10], disease pro-
gression [11, 12], and increased mortality [13]. While
both ART initiation and adherence remain issues for
PWID, it is encouraging to note that former PWID
achieve comparable treatment outcomes as their non-
PWID counterparts [14, 15], and that good results are
attainable in PWID should they remain adherent to their
ART regimen [16].
Methadone maintenance therapy (MMT) is an
evidence-based approach to treating opioid dependence
and reducing illicit opioid use [17]. Within British
Columbia it is widely available through physician’s of-
fices, health authorities, and various private services,
contributing to the fact that 53.3 % of Vancouver PWID
reported MMT use in 2011 [18]. In addition to its effects
on opioid use, MMT is also a useful tool in combatting
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the spread of HIV and has been shown to reduce drug-
related behaviours associated with a high risk of HIV
transmission [19]. In HIV-positive PWID, MMT in-
creases uptake and adherence to ART and improves
overall treatment outcomes [20, 21]. Enrolment in MMT
programs also decreases the incidence of ART discon-
tinuation in this population [22]. Despite these benefits
MMT remains inaccessible in many countries due to
local drug regulations, and the five countries with the
largest injection-drug driven HIV epidemics provide opi-
oid substitution therapy to less than 2 % of their total
populations of PWID [21].
While MMT has been demonstrated as an effective
tool for improving ART treatment outcomes in HIV-
positive PWID, many PWID will decline MMT and rates
of drop out from treatment are high [23]. In this con-
text, the impact that MMT discontinuation has on ART
adherence has not been well described. The following
study was conducted to test the hypothesis that discon-
tinuation of MMT predicts a higher risk of discontinu-
ation of ART in a long-running prospective cohort of
HIV-positive PWID in Vancouver, Canada.
Methods
This study was conducted using data from the AIDS Care
Cohort to Evaluate Access to Survival Services (ACCESS),
an ongoing prospective cohort study of HIV-positive
PWID [24, 25]. Briefly, recruitment for the cohort occurs
through street outreach in the Downtown Eastside of
Vancouver, the regional epicenter for injection drug use.
Participants are eligible if they are a minimum of 18 years
old, are HIV seropositive, and have a history of illicit drug
use. At baseline and semi-annually participants provide
blood samples for virologic and serologic analysis and re-
spond to an interviewer-administered questionnaire elicit-
ing data on demographics, drug use patterns, and
interactions with the criminal justice system. In turn, they
are compensated $20 (CAD) per visit and are offered refer-
rals to addictions treatment and other health services. Data
gathered from the visits is supplemented by information
on HIV treatment received from the local province-wide
drug treatment program (DTP) at the British Columbia
Centre for Excellence in HIV/AIDS (BC-CfE), a centralized
ART dispensary and HIV laboratory for the province of
British Columbia. These data include complete retrospect-
ive and prospective profiles of CD4 counts, plasma HIV-1
RNA viral loads (VL), and history of exposure to specific
antiretroviral agents. The cohort receives annual ethics ap-
proval by the Providence Health Care/University of British
Columbia Research Ethics Board. All individuals provide
written informed consent upon study recruitment.
The study period extended from May 1996 to May 2013.
Participants were eligible for inclusion if they were exposed
to ART at baseline or had initiated ART during follow-up.
For individuals who initiated ART during the study period,
the date of ART initiation was considered their baseline
date. Study eligibility required that individuals had a base-
line CD4 count and viral load measured within 6 months
before or after their baseline date.
The primary outcome of our study was discontinu-
ation of ART, defined as 90 days of continuous ART
non-use following previous enrolment in ART [26]. Dis-
continuation was determined through confidential link-
age with the pharmacy database of the existing
province-wide antiretroviral treatment program. The pri-
mary explanatory variable was methadone status, and
participants at each study visit were categorized as either
MMT non-users, continuous MMT users adherent to
methadone for at least six months, or as prior MMT
users who had discontinued therapy over the previous
six months. This variable was time-varying, as their cat-
egory could change if answers to the question “are you
in a methadone treatment program right now?” were
discordant between 6-month follow-up periods. Patients
consistently on MMT were used as the reference cat-
egory and participants were grouped based on self-
reported data. Potential confounders that were consid-
ered included: gender (male vs. female), age (per 10 years
older), ethnicity (Caucasian vs. other), homelessness
within previous six months (yes vs. no), sex work in-
volvement (yes vs. no), at least daily heroin injection (yes
vs. no), at least daily cocaine injection (yes vs. no), at
least daily crack cocaine smoking (yes vs. no), at least
daily alcohol use (yes vs. no), a protease inhibitor in ini-
tial ART regimen, baseline CD4 count, baseline VL, and
the number of individuals the participant’s ART-
prescribing physician had experience treating at the time
the participant initiated ART (previously demonstrated
to affect the rate of VL suppression [27]). All behav-
ioural variables refer to activities taking place within the
previous 6 months and all variable definitions were iden-
tical to earlier ACCESS reports [24, 25].
Initially, we examined the baseline characteristics of
the analytic sample stratified by methadone use. To test
for significant differences we calculated Pearson’s chi-
squared for categorical variables and the Wilcoxon rank-
sum test for continuous variables. To estimate the
bivariable relationships between each explanatory vari-
able and the time to ART discontinuation, we used Cox
proportional hazards regression. Extended multivariable
Cox proportional hazards regression was then applied to
examine whether methadone status was independently
associated with time to ART discontinuation, after
adjusting for potential confounders [28]. A confounding
model selection approach was used, as previously de-
scribed [29]. Briefly, we fit a multivariate model contain-
ing all variables found to be significantly associated with
ART discontinuation in bivariate analyses (at p < 0.10).
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One secondary variable at a time was then removed in a
stepwise manner to construct reduced models. At each
step the values of the coefficients for methadone status
in the full model was compared with those in the
reduced models. Secondary explanatory variables corre-
sponding to the smallest relative change were removed
sequentially, and the process was continued until the
minimum change from the full model was greater than
5 %. As it is an important clinical variable associated
with eligibility for ART, baseline CD4 count was a priori
retained in the final model despite non-significant re-
sults in the bivariate analysis. Finally, we describe the
median HIV viral load for each methadone use category
using all available data including baseline and follow-up
measures.
Results
In total, 794 HIV-positive PWID were included in the
present analyses between May 1996 and May 2013,
among whom 494 (62.2 %) were male and 451 (56.8 %)
self-identified as Caucasian. The median follow-up time
was 44.9 (interquartile range [IQR]: 24.8–78.5) months.
The median age of participants at baseline was 41.1
(IQR: 34.3–46.6) years old. Table 1 displays additional
socio-demographic, behavioural, social, and clinical data.
When grouped by methadone status at the start time of
the survival analysis, 449 participants (57 %) were not
on MMT, 327 (41 %) were continuously on MMT, and
18 (2 %) had discontinued MMT within the last six
months. Among 794 participants, 377 experienced a
total of 766 ART discontinuation events (defined as
90 days off ART following previous enrolment), for an
incidence density of 27.7 (95 % confidence interval [CI]:
25.1–30.5) per 100 person-years. Among the 794 partici-
pants, 269 (33.9 %) switched their category for MMT
use during follow-up.
Table 2 shows results of the bivariate and multivariate
Cox regression analyses of time to ART discontinuation.
In the bivariate analyses, both being continuously off
MMT (hazard ratio [HR] = 1.36, 95 % CI: 1.12–1.65) as
well as discontinuing methadone (HR = 3.03, 95 % CI:
2.12–4.33) were associated with an increased risk of dis-
continuing ART when compared to consistent MMT
use. Additionally risk factors included homelessness
within the previous six months (HR = 1.94, 95 % CI:
1.57–2.39), sex work involvement (HR = 1.64, 95 % CI:
1.28–2.10), at least daily heroin injection (HR = 2.59,
95 % CI, 2.09–3.21), at least daily cocaine injection
(HR = 2.10, 95 % CI: 1.72–2.58), at least daily crack co-
caine smoking (HR = 1.40, 95 % CI: 1.17–1.68), at least
daily alcohol use (HR = 1.63, 95 % CI: 1.27–2.09), and a
higher baseline VL (per log10 copies/mL; HR = 1.49,
95 % CI: 1.40–1.58). Male gender (HR = 0.71, 95 % CI:
0.58–0.86), older age (per 10 year increase; HR = 0.49,
95 % CI: 0.43–0.55), Caucasian ethnicity (HR = 0.78,
95 % CI: 0.64–0.95), and baseline CD4 count (per 100
cells/mm3; HR = 0.95, 95 % CI: 0.90–0.99) were nega-
tively associated with ART discontinuation.
In the multivariate analysis, both being continuously
off MMT (adjusted hazard ratio (AHR) = 1.44, 95 % CI:
1.19–1.73) and discontinuing MMT (AHR = 1.82, 95 %
CI: 1.27–2.60) were each independently associated with
an increased risk of discontinuing ART.
When we looked at the median plasma HIV viral load
throughout study period, the median viral load was less
than 50 (IQR: 35–1005) copies/mL among individuals
where MMT was used continuously and was 1482 (IQR:
49–39099) copies/mL among individuals who were on
but discontinued MMT in the prior six months.
As a subanalyis, we investigated all possible interactions
between engagement in methadone and all other explana-
tory variables significant in the final multivariable model.
Of these, neither MMT * age (p = 0.085) nor MMT * home-
lessness (p = 0.315) were significantly associated with the
outcome. The interaction terms for MMT *≥ daily heroin
injection (p = 0.008) and MMT * baseline VL (p = 0.012)
were significant. In light of these findings, we fit stratified
models to estimate MMT effects by each level of heroin in-
jection. Among individuals < daily heroin injection, not be-
ing on MMT was associated with ART discontinuation
(AHR= 1.30, 95 % CI: 1.05–1.60) while discontinuing
MMT was not associated with ART discontinuation
(AHR = 1.45, 95 % CI: 0.90–2.34). Among individuals
with ≥ daily heroin injection, both not being on
methadone (AHR = 2.38, 95 % CI: 1.60–3.52) and
MMT discontinuation was associated with ART dis-
continuation (AHR = 3.05, 95 % CI: 1.80–5.19).
Discussion
In this study we examined the relationship with being
off of MMT as well as with discontinuing MMT on ART
discontinuation. Our analysis revealed that participants
not engaged in MMT have a higher likelihood of ART
discontinuation, and additionally demonstrated the inde-
pendent association of MMT discontinuation reducing
time to ART discontinuation. Despite MMT discontinu-
ation occurring within only the previous six-month
period, it is notable that the median VL of these partici-
pants was higher than those who remained on MMT.
Multiple behavioural, social, and structural barriers
complicate the treatment of HIV infection among PWID
[21, 30]. In this setting, it is well documented that on-
going injection drug use contributes to poor ART adher-
ence, and as a result poor health outcomes [7, 8, 13].
MMT has been shown to mitigate these outcomes in
opioid-dependant PWID by enabling initiation of HIV
treatment and by improving ART adherence [20–22].
Our data add further support to the positive effects of
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MMT on optimizing HIV/AIDS treatment outcomes,
while providing evidence suggesting that MMT discon-
tinuation is independently associated with ART discon-
tinuation. This is consistent with studies demonstrating
that other benefits of MMT are improved with extended
duration of methadone treatment including decreased
relapse into drug use, reduction in illegal activity, and in-
creased full-time employment [31, 32]. Interestingly, the
negative consequences of forced discontinuation of
MMT have recently been hypothesized following the
Russian occupation of Crimea and a resulting reversal in
government policy previously supportive of MMT [33].
Our data lends support to the suggestion that such pol-
icy changes could have significant negative impacts on
HIV/AIDS treatment programs in affected regions.
The mechanisms through which remaining on MMT
decreases the discontinuation of ART are likely multifac-
torial. MMT provides a stabilizing effect on opioid use,
encouraging improved social function, social support,
and development of daily routines [34]. These have a
demonstrated positive effect on ART adherence [35].
Furthermore, MMT necessitates regular contact with
Table 1 Baseline demographics of study participants stratified by mmt use (n = 794)
Methadone Status
Variable Total (%) (n = 794) Discontinued MMT (%) (n = 18) Current MMT (%) (n = 327) MMT Naive (%) (n = 449)
Gender
Male 494 (62.2) 9 (50.0) 166 (50.8) 319 (71.1)
Female 300 (37.8) 9 (50.0) 161 (49.2) 130 (28.9)
Age (years)
Median (IQR) 41.1 (34.3–46.6) 37.8 (30.0–42.9) 40.6 (34.2–46.2) 41.6 (34.6–47.2)
Ethnicity
Caucasian 451 (56.8) 12 (66.7) 205 (62.7) 234 (52.1)
Other 343 (43.2) 6 (33.3) 122 (37.3) 215 (47.9)
Homelessnessa
Yes 166 (20.9) 2 (11.1) 68 (20.8) 96 (21.4)
No 625 (78.8) 16 (88.9) 258 (78.9) 351 (78.2)
Sex work involvementa
Yes 125 (15.7) 3 (16.7) 60 (18.4) 62 (13.8)
No 667 (84.0) 15 (83.3) 266 (81.4) 386 (86.0)
Daily heroin injectiona
Yes 131 (16.5) 8 (44.4) 53 (16.2) 70 (15.6)
No 662 (83.4) 10 (55.6) 274 (83.8) 378 (84.2)
Daily cocaine injectiona
Yes 148 (18.6) 5 (27.8) 57 (17.4) 86 (19.2)
No 640 (80.6) 13 (72.2) 268 (82.0) 359 (80.0)
Daily crack cocaine smokinga
Yes 208 (26.2) 4 (22.2) 104 (31.8) 100 (22.3)
No 585 (73.7) 14 (77.8) 222 (67.9) 349 (77.7)
Protease inhibitor initial regimena
Yes 325 (40.9) 11 (61.1) 143 (43.7) 171 (38.1)
No 469 (59.1) 7 (38.9) 184 (56.3) 278 (61.9)
CD4 count (cells/mm3)
Median (IQR) 300 (190–440) 255 (190–310) 320 (180–470) 295 (190–425)
Viral load (log10 copies/mL)
Median (IQR) 3.7 (1.7–4.7) 4.5 (4.0–4.8) 3.5 (1.7–4.7) 3.8 (1.7–4.8)
Physician HIV experienceb
Median (IQR) 60 (14–161) 133 (34–203) 71 (19–185) 52 (11–139)
aRefers to behaviors in the previous six months. b Refers to number of total HIV patients physician has treated prior to initial visit with participant. IQR = inter-quartile range.
Percentages may not sum up to 100 % due to missing data and/or rounding error
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the medical system, allowing for the establishment of
positive patient-provider relationships, providing oppor-
tunities for the management of psychiatric co-
morbidities and medication side effects, and offering
regular access to counselling and other programs. These
are all factors understood to improve ART adherence in
PWID [35].
In response to the beneficial effects of MMT on ART
enrolment and adherence, co-administration has been
studied in multiple models of directly observed therapy
(DOT) or directly administered antiretroviral therapy
(DAART) [36, 37]. In our setting, ART is regularly co-
administered with MMT, which can be prescribed
through community physician’s offices and dispensed by
community pharmacies for witnessed ingestion. A recent
systematic review identified these programs as successful
adherence interventions for HIV-positive PWID in the
short-term [36], while a second meta-analysis also ob-
served a positive effect on virologic, immunologic, and
adherence outcomes, particularly when they target indi-
viduals with a high risk of non-adherence [37]. Of note,
both studies comment on the need for further evaluation
of the long-term benefits of these interventions as initial
intervention effects appeared to wane following comple-
tion of the programs. These results are congruent with
our work, demonstrating that short-term interventions
Table 2 Bivariate and multivariate cox proportional hazards analyses of factors associated with art discontinuation among a sample
of injection drug users in vancouver, canada (n = 794)
Unadjusted Hazard Ratio (HR) Adjusted Hazard Ratio (AHR)
Variable HR 95 % CI p value AHR 95 % CI p value
MMT
Current MMT 1.00 — — 1.00 — —
Not on MMT 1.36 1.12–1.65 0.002 1.44 1.19–1.73 <0.001
Discontinued MMT 3.03 2.12–4.33 <0.001 1.82 1.27–2.60 0.001
Gender
(Male vs. female) 0.71 0.58–0.86 <0.001 — — —
Age
(Per 10 years older) 0.49 0.43–0.55 <0.001 0.59 0.52–0.66 <0.001
Ethnicity
(Caucasian vs. other) 0.78 0.64–0.95 0.015 — — —
Homelessnessa
(Yes vs. no) 1.94 1.57–2.39 <0.001 1.53 1.24–1.87 <0.001
Sex work involvementa
(Yes vs. no) 1.64 1.28–2.10 <0.001 — — —
Daily heroin injectiona
(Yes vs. no) 2.59 2.09–3.21 <0.001 1.70 1.39–2.08 <0.001
Daily cocaine injectiona
(Yes vs. no) 2.10 1.72–2.58 <0.001 — — —
Daily crack cocaine smokinga
(Yes vs. no) 1.40 1.17–1.68 <0.001 — — —
Daily alcohol use
(Yes vs. no) 1.63 1.27–2.09 <0.001 — — —
Protease inhibitor initial regimena
(Yes vs. no) 0.97 0.79–1.19 0.771 — — —
Baseline CD4 count
(Per 100 cells/mm3) 0.95 0.90–0.99 0.025 1.03 0.98–1.07 0.234
Baseline viral load
(Per log10 copies/mL) 1.49 1.40–1.58 <0.001 1.39 1.29–1.50 <0.001
Physician HIV experienceb
(Per # prev. patients) 1.00 1.00–1.00 0.074 — — —
aRefers to behaviors in the previous six months. bRefers to number of total HIV patients physician has treated prior to initial visit with participant
Bach et al. BMC Infectious Diseases  (2015) 15:537 Page 5 of 7
are less effective at improving ART adherence over time.
Our data is further complemented by the recent obser-
vation that act of enrolling in MMT decreases the risk
of ART discontinuation [22], suggesting clearly that
long-term treatment is necessary to maximize the bene-
fits of MMT on ART adherence.
This study has several limitations, in part due to its
nature as an observational cohort study. While our co-
hort is largely representative of the local population of
PWID, the generalizability of our findings to other set-
tings is not known. Additionally, much of our data relies
on self-reporting of sensitive subjects and there is a pos-
sibility of a response bias in our survey results. Third,
data on reasons for discontinuation was not available.
This information could potentially provide further infor-
mation as to which patients are at higher risk, including
those taking particularly complicated ART regimens or
those experiencing significant side effects, and might be
best explored through a future qualitative study. Fourth,
as our study does not include diagnostic screening for
opioid dependence, some misclassification bias may have
been introduced by including individuals not eligible for
MMT. We did, however, include various measures of
illicit drug use in this analysis, and our model-building
protocol indicated that high-intensity cocaine and crack
use did not substantively affect the relationship between
MMT engagement and time to ART discontinuation.
Finally, as this is an observational study we must ac-
knowledge the possibility that the described relationship
between MMT and ART discontinuation is not a causal
one. Factors with known effects on ART adherence not
included in our survey include the presence of psychi-
atric co-morbidities and treatments and the strength of
social supports, which we were unable to incorporate
into our analysis [38]. Despite these limitations, the data
suggesting that MMT plays a positive role in successfully
maintaining patients on ART continues to grow.
Conclusions
This study provides evidence that discontinuing MMT is
independently associated with an increased risk of dis-
continuing ART. These data offer further support for
MMT as an important component of comprehensive
HIV treatment programs, and highlight the need for
evidence-based strategies for retaining PWID on MMT.
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